Top news of the week: 17.02.2022.
Career And Jobs
RNA Editing With New Guides May Improve Genetic Disease Treatments
New RNA editing technology may provide a simpler way to repair disease-causing mutations in RNA without compromising precision or efficiency.
FDA hits Legend Biotech with clinical hold on CAR-T just days ahead of BCMA decision
One of the CAR-T therapies Legend Biotech has lined up behind its lead BCMA candidate has now run into a roadblock. The biotech revealed that the FDA has placed a clinical hold on the Phase ...
Fujifilm Launches $60 Million VC Fund for Early-Stage Biotech
The fund will be used to target partnerships with promising early-stage biotechnology to enhance Fujifilm's life sciences portfolio.
Maryland’s Biotech Tax Incentive Boosts VC Funding with Guaranteed Returns
Since 2016 the state has offered more than $70 million in tax credits to 114 different entities and has generated about $140 million in investments into the state’s life sciences ecosystem.
Biotech vet and ex-Biogen exec Tony Kingsley jumps to a new CEO post
More than six months after Tony Kingsley made an abrupt departure from the helm at Scholar Rock — and just a little more than a year after his arrival — we found out today what his next gig ...
Scoop: Star neuroscientist Asa Abeliovich and OrbiMed are teaming on yet another biotech
It’s been barely a year since Eli Lilly bought his second company, Prevail Therapeutics, for $1 billion, but star Columbia neuroscientist Asa Abeliovich is already launching something new. ...
Ex-FDA interim chief Giroir rejoins biotech world with eyes on $50M fundraising for new infectious disease company
Former FDA Acting Commissioner and Admiral Brett Giroir, M.D., is back in the private sector and jumping into securing a series A for his latest biotech. Altesa BioSciences, which broke ...
HBCU BioTech Fellowship Program
Amgen + HBCU 20x20 are proud to present the HBCU BioTech Fellowship program. This paid 8-week professional development program will prepare and empower 50 HBCU students (and soon-to-be ...